A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study With an Optional Safety Extension Treatment Period up to 6 Months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting beta2 Agonists (LABA), in Patients With Uncontrolled Persistent Asthma

Trial Profile

A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study With an Optional Safety Extension Treatment Period up to 6 Months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting beta2 Agonists (LABA), in Patients With Uncontrolled Persistent Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs AZD 5069 (Primary) ; Fluticasone propionate; Steroid receptor agonists
  • Indications Asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms NIMBUS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 May 2015 Results (n=640) presented at the 111th International Conference of the American Thoracic Society.
    • 22 Sep 2014 Status changed from active no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 31 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top